Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

CVS Health (CVS) is one of the largest healthcare companies in the country, boasting a vertically integrated business that ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its ...

CVS Health Corporation ( NYSE: CVS) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial ...

CVS Health Corp. reported a strong start to 2025, with first-quarter revenue climbing 7% to $94.6 billion, driven by growth across all business segments. Adjusted earnings per share rose sharply ...

Caremark Redcar and Cleveland has expanded its animal-assisted therapy service, CareBark, via the addition of five dogs.

Pharmacy benefit manager subsidiary CVS Caremark will prefer Novo Nordisk’s glucagon-like peptide-1 agonist, or GLP-1, Wegovy on its formulary beginning July 1, and the CVS Pharmacy subsidiary ...

Arkansas took its largest enforcement to date in August, when it fined CVS Caremark, Express Scripts, MedImpact and Magellan Rx Management (now part of Prime Therapeutics) nearly $1.5 million for ...